TriangleNCT01266967 · OUTCOME
Composite of Pharmacokinetic Parameters of GSK2118436 in a Subset of Participants Receiving Dexamethasone
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Day 15
What was measured
This outcome measure could not be analyzed because too few participants participated in the dexamethasone study.
Groups in this outcome
GSK2118436 150 mg: No Prior Local Therapy
Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
GSK2118436 150 mg: Prior Local Therapy
Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
| Group | Source count |
|---|---|
| GSK2118436 150 mg: No Prior Local Therapy | 0 |
| GSK2118436 150 mg: Prior Local Therapy | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- units
- Participants
- description
- This outcome measure could not be analyzed because too few participants participated in the dexamethasone study.
- groups
- description
- Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
- id
- OG000
- title
- GSK2118436 150 mg: No Prior Local Therapy
- description
- Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
- id
- OG001
- title
- GSK2118436 150 mg: Prior Local Therapy
- reporting Status
- POSTED
- time Frame
- Day 15
- title
- Composite of Pharmacokinetic Parameters of GSK2118436 in a Subset of Participants Receiving Dexamethasone
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice